3.50Open3.40Pre Close2 Volume7 Open Interest5.00Strike Price710.00Turnover642.69%IV8.50%PremiumMay 16, 2025Expiry Date3.47Intrinsic Value100Multiplier8DDays to Expiry0.13Extrinsic Value100Contract SizeAmericanOptions Type-0.7687Delta0.2060Gamma0.43Leverage Ratio-0.0265Theta-0.0009Rho-0.33Eff Leverage0.0007Vega
OmniAb Stock Discussion
VERAXA Biotech Enters Co-discovery Alliance with OmniAb for a Novel Bispecific Antibody Drug Conjugate Program
Monday, 5th May at 1:00 am
ZURICH, SWITZERLAND, May 5, 2025 -- VERAXA Biotech AG("VERAXA"), an emerging leader in designing novel cancer therapies and proposed de-SPAC acquisition target of
Voyager Acquisition Corp. (NASDAQ: VACH, "Voyager")), announced today a co-discovery alliance with OmniAb, Inc. (NASDAQ: OABI, "OmniAb")...
OmniAb Doubles Q4 Revenue, Expands to 363 Drug Discovery Programs
*nfa
I'm still going to get my son away from ...
No comment yet